Immuron Limited - SIC # 2840 -

Ticker Exchange SIC # Website Latest Ticker
IMRN Nasdaq 2840 www.immuron.com.au

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Immuron Limited

Immuron IMM-529 IND approved by FDA - Nov 5th, 2025 4:00 am
Immuron Announces Clinical Trial Update - Oct 31st, 2025 4:00 am
Presenting on Emerging Growth Conference 87 Day 1 on October 22. Register to live stream. - Oct 21st, 2025 5:00 am
Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target - Oct 17th, 2025 9:07 am
Immuron Q1 FY26 YoY growth - Oct 13th, 2025 4:00 am
Immuron Submits IMM-529 IND to FDA - Oct 8th, 2025 4:00 am
Immuron Letter to Shareholders – Projects Update - Oct 2nd, 2025 4:00 am
Immuron (IMRN) Posts 49% FY2025 Revenue Growth on Travelan Sales - Sep 30th, 2025 1:05 pm
Immuron Full Year 2025 Earnings: AU$0.023 loss per share (vs AU$0.03 loss in FY 2024) - Aug 31st, 2025 5:32 pm
Immuron partners with InvestorHub - Aug 26th, 2025 8:29 pm
Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live stream - Aug 20th, 2025 5:00 am
Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream - Aug 19th, 2025 5:00 am
Immuron - FY25 global sales exceed projection, up 49% on prior year - Jul 17th, 2025 4:00 am
Immuron Travelan® highest sales in history - Apr 10th, 2025 4:00 pm
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) - Mar 5th, 2025 4:00 am
Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now - Feb 18th, 2025 5:00 am
Immuron Travelan® continued strong sales growth - Jan 17th, 2025 4:00 am
Immuron Announces New Research Collaboration targeting Antimicrobial Resistance - Jan 15th, 2025 4:00 am
Immuron Announces Travelan® Clinical Trial Update - Jan 14th, 2025 4:00 am
Hartshead Resources And 2 Other Promising Penny Stocks On The ASX - Jan 14th, 2025 12:05 am